Table 1. Correlation of ADAR2-editing activity and CDC14B expression in astrocytoma tissues (grade I and IV).
| White matter ctrl (n=3) | Grade I astrocytoma (n=7) | Grade IV astrocytoma (GBM) (n=12) | |
|---|---|---|---|
| Outcome | |||
| Alive (% of patients) | 100 | 100 | 30 |
| Dead (% of patients) | 0 | 0 | 70 |
| KPS scorea | |||
| 100 (% of patients) | 100 | 100 | 10 |
| 80–100 (% of patients) | 0 | 0 | 20 |
| <40 (% of patients) | 0 | 0 | 70 |
| Ki-67 proliferation index | |||
| (% of positive cells exp. as mean of tot samples±s.d.) | ND | 2.1 (±0.7) | 33.5 (±9.2) |
| ADAR2 RNA editing of CDC14B | |||
| (% of editing exp. as mean of tot samples±s.e.m.) | |||
| Site 1 | 27 (±1.5) | 17 (±1) | 15 (±0.7) |
| Site 2 | 1 | 5 (±3) | 0 |
| Site 3 | 7.7 (±0.6) | 5.7 (±1.2) | 2 (±0.8) |
| Site 4 | 4.5 (±0.8) | 5 (±2.6) | 1.9 (±0.9) |
| Site 5 | 3 (±1.2) | 4 (±2) | 1.1 (±0.7) |
| Site 6 | 8.2 (±0.8) | 8 (±1) | 2.8 (±1) |
| Site 7 | 1.9 (±1) | 1 | 0 |
| Site 8 | 47.5 (±3.8) | 31 (±2.4) | 29 (±2.6) |
| Site 9 | 8 (±2.9) | 9 (±1.7) | 9.8 (±2) |
| Site 10 | 7.7 (±4) | 6.5 (±1.2) | 2.5 (±0.9) |
| Site 11 | 9.8 (±2.5) | 2 | 2.2 (±1) |
| Site 12 | 8.7 (±4) | 5 (±2.6) | 0 |
| Site 13 | 24.4 (±2) | 16 (±2.3) | 11 (±2) |
| qRT–PCR of CDC14B mRNAb | |||
| (% of mRNA exp. as mean of tot samples±s.d.) | 10 (±0.1) | 7.5 (±1.1) | 3.2 (±1.5) |
| IHC of CDC14B protein expressionc | |||
| (% of positive cells exp. as mean of tot samples±s.d.) | 90–100 (±7.6) | ⩽90 (±5) | 5 (±1.4) |
a
KPS, Karnofsky Performance Status, from 100 to 0, with 100=normal/healthy status.
b
qRT–PCR mRNA expressed as relative fold increase compared with control set to 10.
c
The percentage of stained cells was measured by scoring 6–10 fields per section (at least five sections were considered) and positive cells were divided by the total number of the Hematoxylin–Eosin cells per microscopic field for each tumor/ctrl samples.